ADIL ADIL
Company Profile ↓Company Overview
ADIL (ADIL) is a publicly traded company listed on with a market capitalization of $4.50M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -61.43% |
| 6 Months: | -22.86% |
| 3 Months: | +153.12% |
| 1 Month: | +39.18% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)83.97 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 62.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 84 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.27M | 1.88M | 1.76M | 1.89M | 2.00M |
| Operating Income | -241.49K | -262.42K | -339.51K | -1.74M | -3.82M | -2.25M | -2.16M | -1.75M | -2.30M | -1.82M | -3.34M | -4.84M | -4.40M | -4.06M | -3.06M | -3.24M | -2.55M | -2.92M | -1.48M | -1.36M | -1.85M | -2.29M | -2.21M | - | -2.27M | -1.88M | -1.76M | -1.89M | -2.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.27M | -1.88M | -1.76M | -1.89M | -2.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.23M | -1.96M | -1.79M | -2.00M | -2.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - |
| Net Income | -264.27K | -292.63K | -378.95K | -1.79M | -8.19M | -2.68M | -2.13M | -1.72M | -2.28M | -1.81M | -3.34M | -4.83M | -4.44M | -4.32M | -2.91M | -3.85M | -3.11M | -2.91M | 1.09M | -1.38M | -6.48M | -2.46M | -2.19M | - | -2.23M | -1.96M | -1.79M | -2.00M | -2.02M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.25 | -0.22 | -0.13 | -3.96 | -3.02 | -0.11 | 0.96 | -1.18 | -2.19 | -0.59 | -0.38 | - | -8.52 | -4.50 | -2.00 | - | -1.48 |
| R&D Expense | 57.86K | 27.80K | 55.51K | 76.89K | 188.44K | 686.91K | 1.21M | 864.28K | 1.06M | 888.01K | 1.85M | 2.05M | 2.32M | 1.69M | 596.34K | 679.97K | 696.07K | 676.43K | 429.90K | 207.13K | 454.28K | 1.01M | 1.03M | - | 746.89K | 732.32K | 521.07K | - | 432.53K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 10.86M | 6.89M | 8.28M | 7.80M |
| Operating Income | -995.29K | -6.99M | -8.24M | -10.93M | - | -10.86M | -6.89M | -8.28M | -7.80M |
| EBITDA | - | - | - | - | - | -10.86M | -6.89M | -8.28M | -7.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -10.80M | -7.00M | -13.20M | -7.98M |
| Tax Provision | - | - | - | - | -94.08K | 0 | 0 | 0 | - |
| Net Income | -1.14M | -11.63M | -8.59M | -10.89M | - | -12.73M | -5.12M | -13.20M | -7.98M |
| Diluted EPS | - | - | - | - | - | -317.75 | -90.00 | -68.01 | -11.93 |
| R&D Expense | 182.11K | 368.46K | 3.97M | 5.85M | 8.40M | 1.95M | 1.27M | 3.23M | 2.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 34.55K | 4.70M | 7.68M | 5.49M | - | 5.73M | 4.74M | 5.04M | 6.67M |
| Current Assets | - | - | - | - | - | - | 4.78M | 3.20M | 4.06M | 6.18M |
| Cash & Equivalents | 87.99K | 18.25K | 3.87M | 6.78M | 4.40M | - | 4.00M | 2.83M | 3.75M | 5.88M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | 1.51M | - | 2.46M | 653.08K | 975.86K | 1.40M |
| Current Liabilities | - | 1.03M | 257.97K | 539.05K | 1.51M | - | 1.79M | 653.08K | 975.86K | 1.40M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 256.96K | 207.38K | - | - | - |
| Total Equity | -103.49K | -997.55K | 4.44M | 7.14M | 3.99M | - | 3.28M | 4.08M | 4.07M | 5.28M |
| Shares Outstanding | - | - | - | - | - | - | 42.70K | 66.54K | 258.98K | 1.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -494.86K | -2.50M | -6.34M | -7.63M | - | -11.19M | -6.81M | -6.92M | -6.49M |
| Investing Cash Flow | 35.12K | - | - | -350.00K | - | 0 | 1.50M | 0 | 150.00K |
| Financing Cash Flow | 390.00K | 6.35M | 9.25M | 5.61M | - | 9.13M | 4.13M | 7.85M | 8.47M |
| Capital Expenditure | - | - | - | - | -64.61K | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | -11.19M | -6.81M | -6.92M | -6.49M |
| Net Change in Cash | - | - | - | - | - | -2.06M | -1.17M | 923.44K | 2.13M |
| Share Buybacks | - | - | - | - | - | - | 1.66K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| ROE % | 114.2% | -261.9% | -120.3% | -273.3% | - | -388.6% | -125.5% | -324.4% | -151.2% |
| ROCE % | 99.8% | -157.3% | -115.5% | -274.2% | - | -275.5% | -168.7% | -203.6% | -147.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADIL
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee and Board of Directors granted Matthew Davidson and Julie Sai…
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street
ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally
Adial on Thursday announced that it has bought privately held Azora Therapeutics.
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 - Azora’s oral candidate, AT177, …
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
The alcohol use disorder market is set to grow due to unmet clinical needs, limited efficacy of current therapies, and rising demand for better-tolerated treatments. Expanding label indications, new regulatory approvals of therapies such as…
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addictio…
ADIL — Frequently Asked Questions
What is the current share price of ADIL?
As of 2026-08-05 17:25 PDT, ADIL trades at $4.05 on NASDAQ/NYSE. Its 52-week range is $1.36 to $10.75.
What is the market capitalisation of ADIL?
ADIL has a market capitalisation of $4.50M on NASDAQ/NYSE.
What is the P/E ratio of ADIL?
ADIL trades at a trailing price-to-earnings (P/E) ratio of -0.34. Its price-to-book (P/B) ratio is 0.85.
Is ADIL a good stock to buy?
This page provides a data-driven analysis of ADIL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.